Author(s): Lippert WC, Gustat J
Abstract Share this page
Abstract OBJECTIVES: Second-hand smoke is associated with an increased risk of adverse health outcomes, such as acute myocardial infarction (AMI) and coronary heart disease (CHD). At present, 38 US states/territories have enacted Clean Indoor Air Acts (CIAAs). The purpose of the current study was to compare the prevalence of self-reported health outcomes on a state/territory-wide level 1 year prior to CIAA implementation and at least 1 year after CIAA implementation for each respective state/territory. STUDY DESIGN: Pre-test, post-test study. METHODS: Seventeen states/territories with pre- and post-CIAA data were included in the current study. All data (AMI, CHD/angina, former and current smoker rates) were collected from the Behavioral Risk Factor Surveillance System (BRFSS) in the year prior to each state/territory's respective CIAA implementation (baseline) and 2009 (most recent year with BRFSS data). RESULTS: Between baseline and 2009, 10 states/territories (58.8\%) had a significant decrease in the prevalence of CHD/angina or AMI, 11 states/territories (64.7\%) had a significant decrease in the prevalence of current smokers, and three states/territories (17.7\%) had a significant decrease in the prevalence of both current and former smokers. Six states/territories (35.3\%) had a significant increase in the prevalence of former smokers. CONCLUSIONS: State/territory-wide CIAAs are beneficial in reducing adverse cardiovascular health outcomes in the short term. The prevalence of AMI, CHD/angina, and former and current smokers decreased significantly following CIAA implementation. The current study adds further support for the passage and implementation of CIAAs on a state/territory-wide level. However, further studies need to be conducted to assess the long-term outcomes of CIAAs. Copyright © 2012 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.
This article was published in Public Health
and referenced in Journal of Antivirals & Antiretrovirals